defactinib + avelumab

Defactinib + avelumab is a combination of two investigational drugs developed for the treatment of advanced epithelial ovarian cancer and other solid tumors. **Defactinib** is a selective small molecule inhibitor of focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase implicated in cancer cell signaling, survival, migration, and resistance to immune-mediated killing. **Avelumab** is a fully human anti-PD-L1 monoclonal antibody that blocks the interaction between programmed death ligand 1 (PD-L1) and its receptor PD-1, thereby restoring anti-tumor immune responses. The aim of combining these agents is to enhance the efficacy of immunotherapy by both suppressing tumor immune evasion (via PD-L1 blockade) and disrupting tumor cell signaling and the immunosuppressive tumor microenvironment (via FAK inhibition)[1][3][5].

Brand names

avelumab (no unique brand for combo)no unique brand for defactinib + avelumab combination

Other names

defactinib + avelumabVS-6063 + avelumab